Italy’s ReiThera Covid vaccine shows strong immune response in trials

The Local Italy
The Local Italy - [email protected] • 15 Jul, 2021 Updated Thu 15 Jul 2021 10:25 CEST
image alt text
A medical worker holds a vial of the ReiThera experimental Covid-19 vaccine at the pharmacy of the Sant'Andrea hospital in Vercelli, Piedmont, on April 15, 2021. - The Sant'Andrea hospital is among the 25 centers throughout Italy in which ReiThera, the 100 percent made in Italy vaccine created by the Spallanzani Institute in Rome, is being tested. (Photo by MARCO BERTORELLO / AFP)

Italy's hopes of producing its own Covid-19 vaccine were boosted this week as ReiThera reported a strong immune response and no serious side effects in second-stage clinical trials.


The ReiThera vaccine, called GRAd-COV2, produced an antibody response in over 93% of volunteers three weeks after the first dose, reaching 99% after the second shot, the company based in Castel Romano near Rome said in a statement on Monday.

ReiThera stated that the results “confirmed what was already observed during Phase 1: the vaccine is well tolerated in the first dose and even better tolerated after the second.”

READ ALSO: Covid-19: How many people in Italy still aren’t vaccinated?

"Adverse events, for the most part of a small or moderate entity and of short duration, are mainly referable to pain and tension at the site of the injection, sense of fatigue, muscular pain and headache", the company went on to say.

"No serious adverse events that could be connected to the vaccine were registered", it said.


The study, which began on March 18th in 24 clinical centers across Italy, involved 917 volunteers, the company said.

The volunteers were divided at random into three groups, receiving either a single vaccine dose followed by a placebo dose, or two vaccine doses, or two doses of placebo, with a three-week interval in between.

ReiThera said two independent advisory boards had recommended advancing the vaccine into the third and final phase of trials, but it was unclear how this may be funded.

The company would need at least 60 million euros ($71 million) for the third phase of studies, but an Italian state audit court recently rejected plans to give it public funding, Reuters reported.

ReiThera has held preliminary talks about potentially supplying its vaccine to the European Union, which is looking to boost its own production of vaccines.

Italy's coronavirus special commissioner said this week that a higher rate of vaccinations is needed in a new "push" to increase coverage, particularly of people in older, more vulnerable age groups.

The country is currently administering around half a million Covid-19 vaccine doses per day.



The Local Italy 2021/07/15 10:25

Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.

Please log in to leave a comment.

See Also